ArticleInternational wound journal2025
Three-Year Recurrence in People With Diabetic Foot Ulcers and Chronic Limb Threatening Ischemia Is Comparable to Cancer.
Article in International wound journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Cellular, Acellular, and Matrix-Like Placental Products for Diabetic Foot Ulcers: A 12-Week Randomised-Trial Meta-Analysis.International wound journal · 2026Pooled it
- High Adherence to Remote Monitoring Technology in Patients at Risk for Diabetic Foot Ulcer.International wound journal · 2026Article
- Comprehensive Management of Diabetic Foot Ulcers: Current Evidence and Practice.Journal of diabetes · 2026Review
- [Medium- and long-term clinical efficacy of tibial transverse transport surgery in the treatment of diabetic foot ulcers].Zhonghua shao shang yu chuang mian xiu fu za zhi · 2026Article
- Exploring Compositions of Cell-Based Therapies for Diabetic Foot Ulcer Treatment: A Review of Clinical Studies.Stem cell reviews and reports · 2026Review
- Piroxicam accelerates diabetic foot ulcer healing via ERα-dependent mitochondrial protection and oxidative stress relief.Frontiers in pharmacology · 2026Article
- Beyond clinical closure: functional skin barrier recovery to prevent diabetic foot ulcer recurrence: a narrative review.Frontiers in endocrinology · 2026Review
- Automated Periosteal Distraction for Limb Salvage in Diabetic Foot Ulcers With Chronic Limb-Threatening Ischemia (Brief Communication).International wound journal · 2026Article
- Development and Validation of a Nursing-Integrated Nomogram to Predict 1-Year Ulcer Recurrence in Patients with Diabetic Foot Ulcers After Endovascular Therapy.Diabetes, metabolic syndrome and obesity : targets and therapy · 2026Article
- Spooky action at a distance: neuromodulation, physiologic distress signals, and limb preservation.Burns & trauma · 2026Review
- Three-Year Recurrence in People With Diabetic Foot Ulcers and Chronic Limb Threatening Ischemia Is Comparable to Cancer.International wound journal · 2025Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aimed to compare the 3-year recurrence rates of diabetic foot ulcers (DFU) and the rate of endovascular reintervention for chronic limb-threatening ischaemia (CLTI) to recurrence rates of advanced-stage cancers. We systematically collected original data reporting 3-year DFU recurrence from studies published through 2024 and calculated a pooled mean. These findings were compared to recurrence rates for advanced breast, prostate, colorectal, and lung cancers using contemporary sources from the National Cancer Institute and American Cancer Society. CLTI reintervention data were drawn from the BEST-CLI trial. The pooled 3-year DFU recurrence rate was 58%, while the CLTI reintervention rate was 50%-comparable to cancer recurrence rates: breast (25%-40%), prostate (30%-40%), colorectal (30%-50%), and lung (60%-80%). Despite these comparable risks, DFU and CLTI remain underrecognized in terms of their recurrent burden on individuals, families, and health systems. The data presented here underscore the need to reframe healed DFU and post-intervention CLTI not as an endpoint but as a remission-a state requiring structured surveillance and proactive management, much like in oncology. Developing interdisciplinary survivorship care plans for individuals with DFU and CLTI, modelled on those used in cancer care, may improve communication, enhance secondary prevention, and foster more ulcer-free, hospital-free, and activity-rich days.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.